Truncated recombinant human SP-D attenuates emphysema and type II cell changes in SP-D deficient mice
2007

Recombinant SP-D Reduces Emphysema in Mice

Sample size: 20 publication 10 minutes Evidence: moderate

Author Information

Author(s): Knudsen Lars, Ochs Matthias, MacKay Rosemarie, Townsend Paul, Deb Roona, Mühlfeld Christian, Richter Joachim, Gilbert Fabian, Hawgood Samuel, Reid Kenneth, Clark Howard

Primary Institution: University of Göttingen

Hypothesis

Does treatment with rfhSP-D reduce structural abnormalities in SP-D deficient mice?

Conclusion

Treatment with rfhSP-D leads to reduced emphysema and corrected type II cell changes in SP-D deficient mice.

Supporting Evidence

  • After 3 weeks of treatment, alveolar number was higher and mean alveolar size was smaller compared to saline-treated controls.
  • Type II cell number and size were smaller as a consequence of treatment.
  • The total volume of lamellar bodies per type II cell and per lung was smaller after 6 weeks of treatment.

Takeaway

Researchers gave a special protein to mice that usually have lung problems, and it helped their lungs get better.

Methodology

SP-D knock-out mice were treated with rfhSP-D and compared to control groups using stereological analysis.

Potential Biases

Potential bias in treatment administration and analysis methods.

Limitations

The study was limited to a specific mouse model and may not fully translate to human conditions.

Participant Demographics

SP-D knock-out mice aged 3 to 12 weeks.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1465-9921-8-70

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication